VADS
CA223-001
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in;Advanced Refractory Solid Tumors
Paris
CHRISTOPHE LE TOURNEAU
VADS
CHECKMATE 651 (CA209-651)
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Paris
CHRISTOPHE LE TOURNEAU
VADS
COPAN-ORL 06
Phase Ib/II trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) harboring a PI3KCA mutation/amplification and/or a PTEN loss. COPAN - ORL06
Paris
CHRISTOPHE LE TOURNEAU
VADS
DEBIO 1143-201
A Phase I/II randomised study to determine the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of Debio 1143 combined with concurrent chemo-radiation therapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Paris
CHRISTOPHE LE TOURNEAU
VADS
DEBIO 1143-202
Pre-operative window-of-opportunity study of Debio 1143 with or without cisplatin in patients with resectable squamous cell carcinoma of the head and neck.
Paris
CHRISTOPHE LE TOURNEAU
Gynécologie
GM102
OPEN, NON CONTROLLED, MULTICENTER, FIRST-IN-HUMAN STUDY FOR THE EVALUATION OF THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF GM102 IN PATIENTS WITH ADVANCED PRETREATED GYNECOLOGICAL CANCER
Paris
CHRISTOPHE LE TOURNEAU
VADS
U31287-A-U203 / Patritumab
RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH CETUXIMAB PLUS PLATINUM-BASED THERAPY IN FIRST LINE SETTING IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK.
Paris
CHRISTOPHE LE TOURNEAU
VADS
Javelin HN100 (B9991016)
A Randomized Double-blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck.
Paris
CHRISTOPHE LE TOURNEAU
Gynécologie
ASCORDIA01
ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses
Paris, Saint-Cloud
CAROLINE MALHAIRE, ROMAN ROUZIER
Sein métastatique HER2+
HER2CLIMB (ONT-380-206)
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Paris
FRANCESCO RICCI